131 related articles for article (PubMed ID: 22094088)
1. [Clinical study of diethylstilbestrol in hormone refractory prostate cancer].
Wang JW; Zhou LQ; Ji SQ; Song G; Li XS; He ZS
Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(32):2247-9. PubMed ID: 22094088
[TBL] [Abstract][Full Text] [Related]
2. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Miyake H; Hara I; Yamazaki H; Eto H
Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
[TBL] [Abstract][Full Text] [Related]
4. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
5. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
Oh WK; Kantoff PW; Weinberg V; Jones G; Rini BI; Derynck MK; Bok R; Smith MR; Bubley GJ; Rosen RT; DiPaola RS; Small EJ
J Clin Oncol; 2004 Sep; 22(18):3705-12. PubMed ID: 15289492
[TBL] [Abstract][Full Text] [Related]
6. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
Heng DY; Chi KN
Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
9. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
11. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.
Moore MM; Stockler M; Lim R; Mok TS; Millward M; Boyer MJ
Cancer Chemother Pharmacol; 2010 Oct; 66(5):845-50. PubMed ID: 20082080
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of prostate-specific antigen levels two months after hormonal manipulation of metastatic prostate cancer.
Kawakami S; Takagi K; Yonese J; Ueda T; Fukui I; Kawai T
Eur Urol; 1997; 32(1):58-63. PubMed ID: 9266233
[TBL] [Abstract][Full Text] [Related]
14. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E
Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
16. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
17. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
18. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
[TBL] [Abstract][Full Text] [Related]
20. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
